These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15339030)

  • 1. Effect of 5-lipoxygenase inhibition on events associated with inflammatory bowel disease in rats.
    Singh VP; Patil CS; Kulkarni SK
    Indian J Exp Biol; 2004 Jul; 42(7):667-73. PubMed ID: 15339030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.
    Rask-Madsen J; Bukhave K; Laursen LS; Lauritsen K
    Agents Actions; 1992; Spec No():C37-46. PubMed ID: 1359745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Lipoxygenase-derived lipid mediators are not required for the development of NSAID-induced inflammatory bowel disease in IL-10-/- mice.
    Narushima S; DiMeo D; Tian J; Zhang J; Liu D; Berg DJ
    Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G477-88. PubMed ID: 18048478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats.
    Zingarelli B; Squadrito F; Graziani P; Camerini R; Caputi AP
    Agents Actions; 1993 Jul; 39(3-4):150-6. PubMed ID: 7905704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.
    Masferrer JL; Zweifel BS; Hardy M; Anderson GD; Dufield D; Cortes-Burgos L; Pufahl RA; Graneto M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):294-301. PubMed ID: 20378715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
    Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
    Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Substances affecting the synthesis and activity of leukotrienes].
    Opletalová V; Hartl J; Bĕhounková M
    Ceska Slov Farm; 1997 Apr; 46(2):51-7. PubMed ID: 9244564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model.
    Melstrom LG; Bentrem DJ; Salabat MR; Kennedy TJ; Ding XZ; Strouch M; Rao SM; Witt RC; Ternent CA; Talamonti MS; Bell RH; Adrian TA
    Clin Cancer Res; 2008 Oct; 14(20):6525-30. PubMed ID: 18927292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
    Pallio G; Bitto A; Pizzino G; Galfo F; Irrera N; Minutoli L; Arcoraci V; Squadrito G; Macrì A; Squadrito F; Altavilla D
    Eur J Pharmacol; 2016 Oct; 789():152-162. PubMed ID: 27450484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke.
    Ye YN; Wu WK; Shin VY; Bruce IC; Wong BC; Cho CH
    Carcinogenesis; 2005 Apr; 26(4):827-34. PubMed ID: 15637091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.
    Ulbrich H; Soehnlein O; Xie X; Eriksson EE; Lindbom L; Albrecht W; Laufer S; Dannhardt G
    Biochem Pharmacol; 2005 Jul; 70(1):30-6. PubMed ID: 15894291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.
    Rossi A; Pergola C; Koeberle A; Hoffmann M; Dehm F; Bramanti P; Cuzzocrea S; Werz O; Sautebin L
    Br J Pharmacol; 2010 Oct; 161(3):555-70. PubMed ID: 20880396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Studies on the influence of Candida fungal colonization on the healing process of inflammatory lesions in the colon in rat animal model].
    Zwolińska-Wcisło M; Brzozowski T; Budak A; Sliwowski Z; Drozdowicz D; Kwiecień S; Trojanowska D; Rudnicka-Sosin L; Mach T; Konturek SJ; Pawlik WW; Targosz A
    Przegl Lek; 2007; 64(3):124-9. PubMed ID: 17941462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease.
    Lamprecht A; Ubrich N; Yamamoto H; Schäfer U; Takeuchi H; Maincent P; Kawashima Y; Lehr CM
    J Pharmacol Exp Ther; 2001 Nov; 299(2):775-81. PubMed ID: 11602694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of different doses of Manuka honey in experimentally induced inflammatory bowel disease in rats.
    Prakash A; Medhi B; Avti PK; Saikia UN; Pandhi P; Khanduja KL
    Phytother Res; 2008 Nov; 22(11):1511-9. PubMed ID: 18688794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation.
    Giannaras A; Selig W; Ellis J; Hullinger T
    Eur J Pharmacol; 2005 Jan; 506(3):265-71. PubMed ID: 15627437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against dextran sodium sulfate-induced colitis by dehydroepiandrosterone and 7alpha-hydroxy-dehydroepiandrosterone in the rat.
    Pélissier MA; Muller C; Hill M; Morfin R
    Steroids; 2006 Mar; 71(3):240-8. PubMed ID: 16371229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
    Chen X; Wang S; Wu N; Sood S; Wang P; Jin Z; Beer DG; Giordano TJ; Lin Y; Shih WC; Lubet RA; Yang CS
    Clin Cancer Res; 2004 Oct; 10(19):6703-9. PubMed ID: 15475461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.
    Vidal C; Gómez-Hernández A; Sánchez-Galán E; González A; Ortega L; Gómez-Gerique JA; Tuñón J; Egido J
    J Pharmacol Exp Ther; 2007 Jan; 320(1):108-16. PubMed ID: 17015640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of N-aryl-4-aryl-1,3-thiazole-2-amine derivatives as direct 5-lipoxygenase inhibitors.
    Suh J; Yum EK; Cheon HG; Cho YS
    Chem Biol Drug Des; 2012 Jul; 80(1):89-98. PubMed ID: 22404847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.